Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/jbi-802-initial-phase-i-data-suggests-therapeutic-potential-in-sensitizing-immunotherapy-resistant-tumors-and-in-myeloproliferative-neoplasms-with-thrombocytosis-302028480.html
https://www.prnewswire.com/news-releases/jubilant-therapeutics-inc-appoints-nadir-patel-as-an-independent-member-of-its-board-of-directors-301852053.html
https://www.prnewswire.com/news-releases/jubilant-therapeutics-incs-selective-orally-administered-pad4-inhibitor-demonstrates-activity-in-rheumatoid-arthritis-preclinical-models-301796864.html
https://www.prnewswire.com/news-releases/jubilant-therapeutics-inc-receives-orphan-drug-designation-for-the-prmt5-inhibitor---jbi-778-for-the-treatment-of-glioblastoma-multiforme-gbm-301745105.html
https://www.clinicaltrialsarena.com/news/jubilant-solid-tumour-trial/
https://www.prnewswire.com/news-releases/jubilant-therapeutics-inc-announces-us-fda-clearance-of-ind-for-jbi-778-an-oral-brain-penetrant-and-selective-prmt5-inhibitor-for-treatment-of-solid-tumors-with-brain-metastases-and-primary-brain-tumors-301599109.html
https://www.prnewswire.com/news-releases/jubilant-therapeutics-inc-reports-development-of-orally-available-and-brain-penetrant-small-molecule-inhibitors-of-pd-l1-at-the-2022-american-society-of-clinical-oncology-asco-annual-meeting-301558856.html
https://www.prnewswire.com/news-releases/jubilant-therapeutics-inc-doses-first-patient-in-phase-iii-trial-evaluating-jbi-802-dual-inhibitor-of-lsd1-and-hdac6-in-patients-with-advanced-solid-tumors-301533011.html
https://www.prnewswire.com/news-releases/jubilant-therapeutics-inc-reports-isoform-selective-pad4-inhibitors-demonstrating-high-in-vitro-selectivity-and-potency-and-in-vivo-oral-bioavailability-and-anti-tumor-activity-301522802.html